In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

John Carroll

Editor & Founder

After spending the past 8 years scripting a turnaround that would make AstraZeneca $AZN a reliable growth story and global performer in oncology, CEO Pascal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

RFK Jr. spars with senators over research cuts, HHS budget plan

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

In an end-of-year sur­prise, As­traZeneca nabs rare dis­ease stal­wart Alex­ion in $39B buy­out. But why?

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

In an end-of-year surprise, AstraZeneca nabs rare disease stalwart Alexion in $39B buyout. But why?